ReviewInternational journal of nanomedicine2008
Radionuclide carriers for targeting of cancer.
Review in International journal of nanomedicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 105 citations in OpenAlex.
- Radium-223 dichloride in prostate cancer: proof of principle for the use of targeted alpha treatment in clinical practice.European journal of nuclear medicine and molecular imaging · 2020Pooled it
- Heating Induced Nanoparticle Migration and Enhanced Delivery in Tumor Treatment Using Nanotechnology.Bioengineering (Basel, Switzerland) · 2024Review
- Behaviour, use and safety aspects of astatine-211 solvated in chloroform after dry distillation recovery.Scientific reports · 2024Article
- Review
- Targeting the Oxytocin Receptor for Breast Cancer Management: A Niche for Peptide Tracers.Journal of medicinal chemistry · 2024Review
- Targeted Radium Alpha Therapy in the Era of Nanomedicine: In Vivo Results.International journal of molecular sciences · 2024Review
- Radiometals in Imaging and Therapy: Highlighting Two Decades of Research.Pharmaceuticals (Basel, Switzerland) · 2023Review
- PVA-Microbubbles as a Radioembolization Platform: Formulation and the In Vitro Proof of Concept.Pharmaceutics · 2023Article
- The application of radionuclide therapy for breast cancer.Frontiers in nuclear medicine · 2023Review
- Predicting response of micrometastases with MIRDcell V3: proof of principle withEuropean journal of nuclear medicine and molecular imaging · 2022Article
- Matrices and Affinity Ligands for Antibody Purification and Corresponding Applications in Radiotherapy.Biomolecules · 2022Review
- Article
- Preliminary evaluation of alpha-emitting radioembolization in animal models of hepatocellular carcinoma.PloS one · 2022Article
- Microspheres Used in Liver Radioembolization: From Conception to Clinical Effects.Molecules (Basel, Switzerland) · 2021Review
- Synthesis of Radiolabeled Technetium- and Rhenium-Luteinizing Hormone-Releasing Hormone (ACS omega · 2021Article
- Mechanistic Insights into Synergy between Melanin-Targeting Radioimmunotherapy and Immunotherapy in Experimental Melanoma.International journal of molecular sciences · 2020Article
- Preclinical Voxel-Based Dosimetry in Theranostics: a Review.Nuclear medicine and molecular imaging · 2020Review
- Towards elucidating the radiochemistry of astatine - Behavior in chloroform.Scientific reports · 2019Article
- Beyond the Barrier: Targeted Radionuclide Therapy in Brain Tumors and Metastases.Pharmaceutics · 2019Review
- Formulation design, characterization, and in vitro and in vivo evaluation of nanostructured lipid carriers containing a bile salt for oral delivery of gypenosides.International journal of nanomedicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review describes strategies for the delivery of therapeutic radionuclides to tumor sites. Therapeutic approaches are summarized in terms of tumor location in the body, and tumor morphology. These determine the radionuclides of choice for suggested targeting ligands, and the type of delivery carriers. This review is not exhaustive in examples of radionuclide carriers for targeted cancer therapy. Our purpose is two-fold: to give an integrated picture of the general strategies and molecular constructs currently explored for the delivery of therapeutic radionuclides, and to identify challenges that need to be addressed. Internal radiotherapies for targeting of cancer are at a very exciting and creative stage. It is expected that the current emphasis on multidisciplinary approaches for exploring such therapeutic directions should enable internal radiotherapy to reach its full potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.